Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life
Academic Article
Overview
MeSH Major
Carcinoma, Renal Cell
Kidney Neoplasms
Laparoscopy
Nephrectomy
Robotic Surgical Procedures
abstract
Increased monitoring among men with mPCa significantly increases health care costs, without a definitive improvement in survival nor quality of care at EOL noted. Monitoring for disease progression outside of clinical trials should be reserved for those in whom findings will change management. Cancer 2018. © 2018 American Cancer Society.
publication date
published in
Research
keywords
Identity
Language
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
has global citation frequency